

What are Erythropoietin Drugs Market products used for?

The market across North America held the largest share in 2020, accounting for more than one-third of the market.

PORTLAND, OREGON, UNITED STATES, September 22, 2021 /

EINPresswire.com/ -- Rise in prevalence of cancer, HIV, anemia, and kidney diseases, surge in level of awareness about the benefits of EPO therapeutics, and commercialization for erythropoietin biosimilars drive the growth of the global erythropoietin drugs market. However, longer


duration of treatment, unaffordability of therapeutics, and adverse amount of side effects hinder the market growth. On the contrary, the commercialization of darbepoetin alfa biosimilar and achieving economies of scale across developed regions are expected to open lucrative opportunities for the market players in the future.

Global Erythropoietin Drugs Market was pegged at \$9.24 billion in 2020, and is estimated to reach \$14.41 billion by 2028, growing at a CAGR of 5.7% from 2021 to 2028.

Rising incidences of Cancer, ESRD (End Stage Renal Disease), and HIV have largely contributed to the overwhelming demand for EPO drugs. Approximately 20% of the patients suffering from Cancer/HIV and ~70% of the patients suffering from ESRD undergo chemotherapy, which induces anemia in such patients, requiring EPO treatment. Despite this, the market nevertheless witnesses restraints due to highly priced EPO drugs resulting in minimal adoption. However, commercialization of EPO biosimilars would eventually ease the influence of restraints and fuel the market growth, primarily across the developing regions.

For Right Perspective and Competitive Insights, Get Sample Report at:

<https://www.alliedmarketresearch.com/request-sample/59>



Growth of the market is driven by rise in number of treatment cycles for chemotherapy and increase in number cases including cancer, HIV, kidney diseases, and anemia.

Covid-19 scenario:

The outbreak of Covid-19 disrupted the workflow in the healthcare sector as the rapid spread of coronavirus forced several industries to shut down temporarily.

However, the pandemic had a positive effect on the demand for medical services including erythropoietin.

As erythropoietin is used to treat anemia and can be effective against Covid-19, which boosted its demand. Moreover, it has anti-ischemic, anti-apoptotic, and regenerative effects in several tissues such as kidney, lungs, nervous system, retina, and pancreas. Thus, it can be used to treat critically ill patients.

Based on product type, the epoetin-alfa segment held the lion's share in 2020, accounting for more than two-fifths of the market. However, the darbepoetin-alfa segment is estimated to register the highest CAGR of 7.0% during the forecast period.

Key market players-

Johnson & Johnson

Amgen Inc.

Roche, Hospira Inc.

Biocon

LG Life Sciences Ltd.

Teva Pharmaceutical Industries Ltd.

Intas Pharmaceuticals

Ranbaxy Laboratories Ltd

Celltrion, Inc.

North America dominates the global erythropoietin drugs market, owing to presence of several approved and commercialized erythropoietin biosimilars. However, Asia-Pacific is characterized by presence of generic epoetin products. Asia-Pacific and LAMEA offer promising growth opportunities for erythropoietin manufacturers as these regions are less explored for erythropoietin drugs as compared to North America and Europe.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert:

<https://www.alliedmarketresearch.com/purchase-enquiry/59>

We have also published few syndicated market studies in the similar area that might be of your interest. Below are the report title for your reference, considering Impact of Covid-19 over This Market which will help you to assess aftereffects of pandemic on short-term and long-term growth trends of this market.

Trending Reports In Healthcare Industry:

[COPD and Asthma Devices Market](#) - Global Opportunity Analysis and Industry Forecast, 2020–2027

[Advanced Wound Care Market](#)- Global Opportunity Analysis and Industry Forecast, 2019–2028

About Us:

Allied Market Research (AMR) is a full-service market research and business -consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa

Allied Analytics LLP

+1 503-894-6022

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/552044367>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.